Blood glucose reduction via multi-target metabolic modulation

"Blood glucose reduction via multi-target metabolic modulation" refers to a therapeutic approach that lowers blood glucose not by acting on a single receptor, enzyme, or hormone, but by simultaneously influencing multiple metabolic pathways or regulatory molecules. This strategy is central in type 2 diabetes treatment, leveraging various drugs and interventions that may modulate insulin secretion, insulin sensitivity, hepatic glucose production, glucose absorption, and satiety hormones. It does not denote a single molecular entity or drug target, but rather encompasses the coordinated pharmacological or physiological alteration of several nodes of the glucose metabolic network to achieve effective glycemic control.

Other names

Multi-target blood glucose modulationMulti-targeted glucose lowering

Enhancing insulin secretion (e.g., sulfonylurea); Improving insulin sensitivity (e.g., metformin, thiazolidinediones); Inhibiting glucose reabsorption in kidney (e.g., SGLT2 inhibitors); Slowing carbohydrate digestion/absorption (e.g., alpha-glucosidase inhibitors); Increasing incretin effect (e.g., DPP-4 inhibitors, GLP-1 agonists); Reducing hepatic glucose output (e.g., metformin); Delaying gastric emptying, increasing satiety (e.g., GLP-1 agonists, amylin analogs)